Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies
about
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disordersSystems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemIdentification of residue-to-residue contact between a peptide ligand and its G protein-coupled receptor using periodate-mediated dihydroxyphenylalanine cross-linking and mass spectrometryMetabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients.Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptidesTherapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.Central role of the EGF receptor in neurometabolic aging.Neuropeptides: keeping the balance between pathogen immunity and immune toleranceCerebellum Transcriptome of Mice Bred for High Voluntary Activity Offers Insights into Locomotor Control and Reward-Dependent Behaviors.PACAP Inhibits β-cell Mass Expansion in a Mouse Model of Type II Diabetes: Persistent Suppressive Effects on Islet DensityMass spectrometry based tools to investigate protein-ligand interactions for drug discovery.Stabilized helical peptides: overview of the technologies and therapeutic promises.Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.Mechanistic Contributions of Biological Cofactors in Islet Amyloid Polypeptide Amyloidogenesis.Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration.
P2860
Q24562763-8DE7E44A-9030-41EA-8143-DD20EEBE895EQ26999386-E5D74258-79B2-4061-8103-C8683CF1E0C4Q33711124-AC0C4067-A70E-4BEC-836D-A000FE0C03BFQ33789754-CFE6AA04-EEB1-4369-A3A3-0FC7DA02AEF6Q34128861-B1109655-20D3-4962-8DCB-83F939F50D1CQ34259060-6CA9A73E-63AD-4397-9D0D-01EF8BC74121Q34285619-79E562DE-F62A-45C2-B35E-71E7467CC285Q36158715-FFC62D0F-7E28-432C-90CA-81BD2F00A023Q36205750-EBEEDBD0-CE15-42D0-ADE2-2BCEDF5C5456Q36672151-9EAA446A-55C9-4804-AD16-4DDB25E25940Q38005330-84417BF4-FEFE-4FAC-BF2D-2D8501F93AD9Q38014489-5EAC490E-4C03-4B28-AD51-CE4BFE51F3CBQ38071991-C17C0906-8203-4C15-888A-7C0B31D0CAF4Q38635739-4B2D21D8-7AE1-4594-96FF-D5A033EAD2FAQ38697831-E9A0580B-B065-487C-93E1-11CBD2EDF6CEQ51547850-B9C31269-A162-4EE0-BFDD-D795F9DB6632
P2860
Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Chemical modification of class ...... rine pharmacological therapies
@ast
Chemical modification of class ...... rine pharmacological therapies
@en
type
label
Chemical modification of class ...... rine pharmacological therapies
@ast
Chemical modification of class ...... rine pharmacological therapies
@en
prefLabel
Chemical modification of class ...... rine pharmacological therapies
@ast
Chemical modification of class ...... rine pharmacological therapies
@en
P2093
P2860
P1476
Chemical modification of class ...... rine pharmacological therapies
@en
P2093
Angela DeRidder
Bronwen Martin
Caitlin M White
Megan C Chapter
Stuart Maudsley
Wayne Chadwick
P2860
P356
10.1016/J.PHARMTHERA.2009.07.006
P577
2009-08-15T00:00:00Z